Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of participants previously enrolled in iECURE investigational product protocols
2024-514190-21-00Phase 2Authorised
- Sponsor
- iECURE
- Start
- Jun 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Other Nucleases → Programmable Nucleases → Gene Editing → Gene Therapies
- Countries
- 6
01
Overview
Phase 2, open-label trial of ECUR-506D and ECUR-506A in ornithine transcarbamylase deficiency (3 arms), sponsored by iECURE. Primary endpoint: Long-term safety and clinical monitoring. Planned start Jun 2026; status: authorised.
02
Drugs
ECUR-506DECUR-506A
03
Conditions
ornithine transcarbamylase deficiency
Beyond the preview
Go deeper on 2024-514190-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514190-21-00.